Interim Report • Jul 24, 2025
Interim Report
Open in ViewerOpens in native device viewer

30th June 2025
Paris, July 24, 2025 - LISI today announces its results for the first half of the year ended June 30, 2025. These financial statements have been reviewed by the Statutory Auditors and were presented to the Board of Directors at its meeting held today.
| Six months ended June 30 | H1 2025 | H1 2024 | Change | ||||
|---|---|---|---|---|---|---|---|
| Key items in the income statement | |||||||
| Revenue | M | 978.8 | 903.6 | + 8.3% | |||
| EBITDA | € million | 147.3 | 107.2 | + 37,4% | |||
| EBIT | € million | 95.6 | 54.0 | + 77.1% | |||
| Current operating margin | % | 9.8 | 6.0 | + 3.8 pts | |||
| Net income for the period attributable to equity holders of the company |
€ million | 38,5 | 31,6 | + 22.0% | |||
| Diluted earnings per share | € | 0.83 | 0.68 | + 22.1 % | |||
| Main items in the cash flow statement | |||||||
| Cash flow from operations | € million | 88.8 | 86,0 | +2.8 €m | |||
| CAPEX | € | 52.7 | 55.5 | - 2.8 €m | |||
| Free Cash Flow1 | M | -14,3 | -13,3 | -1,0 €m | |||
| Key elements of the financial position | |||||||
| H1 2025 | 12/31/2024 | ||||||
| Net financial debt | € million | 519.7 | 488.5 | + 31.2 €m | |||
| Gearing | % | 52.8% | 48.6% | + 4.2 pts |
1 Free Cash Flow: cash flow from operations less net capital expenditure and changes in working capital
| Revenue in €m | 2025 | 2024 | 2025/2024 | At constant scope and exchange rates |
|---|---|---|---|---|
| Q1 | 486.7 | 449.3 | +8.3% | +7.5% |
| Q2 | 492.1 | 454.3 | +8.3% | +11.9% |
| Six months ended June 30 | 978.8 | 903.6 | +8.3% | +9.7% |
Consolidated revenue for the first half of 2025 amounted to 978.8 €m, up +8.3% compared to the same period in 2024, taking into account the following factors:
In line with the objective of maintaining positive organic growth in 2025, revenue adjusted for currency and scope changes rose by 9.7% to the first six months of the year.
The current EBITDA margin reached 15.1% of revenue, up 3.2 points compared to the same period last year. It benefited from significant leverage, thanks in particular to:
The effect of provisions and reversals (mainly on inventories) was favorable compared with the first half of 2024, amounting to 0.6 €m. They had been negative in the first half of 2024 (-1.0 €m).
EBIT amounted to 95.6 €m, up by +41.6 €m, representing a current operating margin of 9.8% compared with 6.0% in the first half of 2024.
Non-recurring operating income and expenses amounted to -3.4 €m, compared with -3.1 €m in the first half of 2024. They mainly relate to the continuation of the Forge 2022 project and industrial reorganizations in the LISI AUTOMOTIVE division.
The financial result amounted to -40.0 €m (-8.4 €m in H1 2024). This is mainly due to the following factors:
• the effects of the revaluation of foreign currency-denominated debts and receivables and the change in the fair value of hedging instruments (-29.2 €m compared with +3.6 €m in H1 2024), which includes a latent foreign exchange loss reflecting the depreciation of the dollar against the euro, particularly on cash and cash equivalents denominated in dollars,
• financial expenses, corresponding to the cost of long-term net debt, amounted to -13.1 €m (-14.6 €m in H1 2024). Gains on cash investments amounted to +2.3 €m (+2.6 €m in H1 2024).
The corporate income tax rate was 25.8%, in line with the Group's historical rates.
Net income amounted to 38.5 €m (3.9% of revenue), compared with 31.6 €m (3.5% of revenue) in the first half of 2024.
At 88.8 €m, cash flow from operations increased compared to the same period last year (86.0 €m) and represents 9.1% of revenue. It covers the entire financing requirement for investment programs of 52.7 €m (5.4% of revenue). These investments are mainly devoted to the pursuit of strategic initiatives aimed at stimulating future growth, the development of new products, innovation and the implementation of multi-year industrial programs.
Working capital requirements (79 days of revenue) decreased by four days compared to the same period last year. The number of days of inventory remained stable at 103 days at the end of June, taking into account anticipated future growth.
Free cash flow stood at -14.3 €m (-13.3 €m in H1 2024). Adjusted for the unfavorable impact of the weakening of the dollar against the euro, as explained above in the financial result, operating free cash flow was positive at +17.6 €m.
Net financial debt stood at 519.7 €m in the first half of 2025. It represents 52.8% of equity and 2.1x current EBITDA. It is well below the covenants authorized by the banking partners, set at 120% of equity and 3.5x current EBITDA.
| Revenue in €m | 2025 | 2024 | 2025/2024 | At constant scope and exchange rates |
|---|---|---|---|---|
| Q1 | 294.4 | 252.5 | +16.6% | +14.4% |
| Q2 | 306.5 | 252.5 | + 21.4% | + 24.8% |
| 6 months ended June 30 | 600.8 | 505.0 | + 19.0% | +19.6% |
The favorable long-term outlook for the global commercial aviation market, confirmed at the Paris Air Show, is reflected in the high level of orders recorded by manufacturers.
The visibility of order books is very good for 2025. Production rates are increasing for the Airbus A320 family (currently 61 aircraft, with a target of 75 in 2027) and for the A350 program. In addition, the resumption of production rates for the B737 MAX and B787 programs at Boeing has largely limited the impact of the strike at the end of 2024 on the first half of 2025.
The significant return of long-haul orders and the resilience of the helicopter and military market segments, which account for between 10% and 15% of the division's business, are supporting demand over the long term.
LISI AEROSPACE division revenue amounted to 600.8€m in the first half of 2025, up +19.0% compared to the same period in fiscal year 2024.
The ramp-up of single-aisle aircraft and maintenance activities benefited all product lines. The "Fasteners" segment grew by +17.7% in Europe, driven by Airbus and the gradual ramp-up of the A350 program. In the United States, the "Fasteners" segment benefited from Boeing's ramp-up and a catchup effect on sales prices achieved with a time lag compared to Europe. As a result, revenue rose by +25.6% compared to the same period last year. The "Structural Components" business posted growth of +15.5% compared with the first half of 2024 and is facing strong demand.
The increase in revenue for the LISI AEROSPACE division, adjusted for currency fluctuations and excluding scope effects, was +19.6% in the first half of 2025.
The division is gradually benefiting from higher volumes, productivity gains following significant recruitment in the two previous financial years, and the ongoing optimization of production flows.

The current EBITDA margin thus gained +3.4 points compared with the same period last year, reaching 17.1% of revenue. EBIT increased 1.8 times compared with the first half of 2024, reaching 74.4 €m for the half-year. The current operating margin improved by 4.4 points compared with the same period last year, reaching 12.4% of the division's revenue.
The division's Free Cash Flow increased significantly compared to the first half of 2024 (1.4 €m as of June 30, 2025, compared to -21.9 €m as of June 30, 2024). This was mainly due to a significant increase in cash flow from operations and the contribution of certain customers to the financing of raw material inventories in a context of rising production.
Capital expenditure amounted to 31.9 €m and were mainly intended to strengthen production capacity in response to increased customer demand and to improve industrial productivity.
| Revenue in €m | 2025 | 2024 | 2025/2024 | At constant scope and exchange rates |
|---|---|---|---|---|
| Q1 | 148.3 | 157.3 | -5.7% | -3.7% |
| Q1 | 143.8 | 153.3 | -6.2% | -3.2% |
| Six months ended June 30 | 292.1 | 310.6 | -6.0% | -3.5% |
Global light vehicle registrations rose by 4.9% compared with the same period last year. Global sales in terms of registrations rose slightly in all markets. China was the most dynamic market (+11.5%), followed by North America (+3.7%) and Europe (+0.1%).
LISI AUTOMOTIVE's revenue amounted to 292.1 €m in the first half of 2025, down -6.0% compared to the same period in 2024.
At constant exchange rates and restated for the disposal of LISI AUTOMOTIVE NOMEL, the decline was limited to -3.5% in the first half of 2025.
Revenue is in line with the decline in global production (estimated at -4.0%(1) for LISI AUTOMOTIVE division's automotive customers), demonstrating the division's resilience in a difficult market.
New product orders remained at a high level of 12.3% of revenue for the half-year (13.6% in the first half of 2024). They are particularly strong in "Clipped Solutions" in Europe and the United States and in "Safety Mechanical Components" in the braking sector in particular.
In this environment, the division's solid financial performance in the first half of 2025 was the result of the cost optimization measures implemented with discipline in recent years.
As a result, current operating income (EBITDA) rose by +20.9% compared with the same period last year to 32.3 €m (11.1% of revenue), compared with 26.7 €m in the first half of 2024 (8.6% of revenue). It benefited not only from lower fixed costs but also from the shift in the product portfolio towards higher value-added parts.
With an EBIT of 14.2 €m, up +54.6% compared to the first half of 2024, the operating margin gained +1.9 point to 4.9%.
The increase in cash flow from operations and inventory management tailored to needs resulted in free cash flow of 5.0 €m, up +4.0 €m compared to the first half of 2024. This takes into account continued investments in new product development and industrial productivity improvements.
LISI MEDICAL (9% of total consolidated revenue)
| Revenue in €m | 2025 | 2024 | 2025/2024 | At constant scope and exchange rates |
|---|---|---|---|---|
| Q1 | 44.7 | 39.7 | +12.5% | +11.0% |
| Q2 | 42.4 | 48.8 | -13.1% | -9.8% |
| Six months ended June 30 | 87.1 | 88.5 | -1.6% | -0.5% |
The global market for medical implants confirmed its structural growth momentum in the first half of 2025, still driven by demand for technical and innovative products.
LISI MEDICAL's revenue amounted to 87.1 €m in the first half of 2025, down -1.6% compared to the same period last year. This decline is the result of a temporary adjustment in response to rising demand in Europe and a slowdown in the United States, ahead of an expected recovery in the second half of 2025.
At constant exchange rates and with no changes in scope, revenue was stable (-0.5%) compared to the first half of 2024.
EBITDA amounted to 14.2 €m (16.3% of revenue), up compared with the same period last year (13.1 €m and 14.8% of revenue). The division benefited from the resolution of raw material supply disruptions, which had temporarily affected production organization in 2024, and improved its overall operating parameters.
EBIT rose to 9.2 €m (+36.6% compared to H1 2024). The current operating margin reached 10.6%, up +3.0 points compared to 7.6% in the first half of 2024.
Working capital requirements have been adjusted to the level of activity, enabling the division to maintain positive free cash flow of 2.0 €m (2.3% of revenue) and thus finance investments mainly aimed at increasing new production capacity to support the growth of new products.
The gradual ramp-up confirms that demand remains strong over the long term in civil aerospace across all platforms. All other market segments, including helicopters and military, are also dynamic.
In addition, LISI AEROSPACE announces the renewal of its "Fasteners" contract with Airbus, which is the division's largest contract and demonstrates Airbus' renewed confidence in the expertise and performance of the solutions offered by LISI AEROSPACE. It consolidates a long-standing partnership spanning several decades and positions LISI AEROSPACE as a strategic long-term supplier for the European manufacturer.
The order books for the LISI AUTOMOTIVE division remain stable in the short term, supported by a good positioning on new vehicles and a consistently high level of new product orders in a global automotive market that remains marked by low visibility.
The division is supporting this trend by adapting its geographical footprint and lowering its break-even point.
In addition, on April 19, LISI AUTOMOTIVE submitted a non-binding offer and signed an exclusive agreement for a period of six months to acquire the assets of a Hungarian company specializing in plastic assembly components. This Hungarian facility would enable the Clipped Solutions Business Group to accelerate its development with its ecosystem of automotive customers (OEMs and Tier1) based in Central Europe. The transaction could be completed in the second half of the year.
The long-term growth prospects for minimally invasive robotic surgery and orthopedic reconstruction remain very promising. The division benefits from a robust order book. The focus will be on the continued development of new products and increasing production volumes, leveraging the recently completed expansion of the Big Lake site in the United States.
This project aims to accelerate the next phase of LISI MEDICAL's development by enabling it to benefit from SK CAPITAL's solid experience in the life sciences sector and its leading expertise in France. They will also provide the financial strength needed to support the company in the long term. LISI MEDICAL will thus be able to expand its offering and capabilities, while strengthening its position as a leading partner to major MedTech players.
In addition, LISI Group plans to become a partner in SK CAPITAL's development strategy by acquiring a 10% stake in the holding company that owns the entire business acquired by SK CAPITAL, thereby joining the planned transformation project.
The transaction remains subject to consultation with the employee representative bodies of the French entities concerned and to the obtaining of the necessary authorizations. Subject to obtaining these authorizations and approvals, the transaction could be completed in the second half of 2025.
Once completed, this transaction will have a significant impact on the Group's consolidated financial statements. It should result in a sharp increase in net income in 2025 and a significant reduction in net financial debt, particularly the 2022 loan facilities repayable without penalty.
The solid performance in the first half of the year strengthens the LISI Group's confidence in achieving the 2025 objectives set last February: to improve its main financial indicators, in particular EBIT, for the third consecutive year, while maintaining positive free cash flow generation.
Nevertheless, the Group remains vigilant in the face of global geopolitical and macroeconomic uncertainties, particularly changes in customs policies and currency exchange rates.
With its strengthened financial position, the Group is confident that it will consolidate its global leadership positions in its chosen niche markets in the future.
| (in thousands of euros) | 06/30/2025 | 06/30/2024 |
|---|---|---|
| REVENUE EXCL. TAX | 978 779 | 903 588 |
| Changes in inventories, finished products and production in progress | 18 839 | 31 834 |
| Total production | 997 617 | 935 421 |
| Other income | 30 236 | 26 042 |
| TOTAL OPERATING REVENUES | 1 027 853 | 961 463 |
| Consumed goods | (292 132) | (289 308) |
| Other purchases and external expenses | (221 743) | (209 352) |
| Taxes and duties | (8 202) | (7 913) |
| Employee benefits expense (including temps) | (358 456) | (347 706) |
| EBITDA | 147 319 | 107 184 |
| Depreciation | (52 287) | (52 167) |
| Net provisions | 617 | (1 005) |
| CURRENT OPERATING PROFIT (EBIT) | 95 649 | 54 011 |
| Non-recurring operating income and expenses | (3 443) | (3 082) |
| OPERATING PROFIT | 92 207 | 50 929 |
| Financing expenses and revenue on cash | (10 896) | (12 001) |
| Revenue on cash | 2 289 | 2 651 |
| Financing expenses | (13 186) | (14 653) |
| Other financial income and expenses | (29 148) | 3 638 |
| Other financial items | 12 290 | 7 534 |
| Other interest expenses | (41 438) | (3 896) |
| Taxes (including CVAE (Tax on Companies' Added Value)) | (13 451) | (11 361) |
| PROFIT (LOSS) FOR THE PERIOD | 38 710 | 31 204 |
| Attributable as company shareholders' equity | 38 506 | 31 571 |
| Interest not granting control over the company | 204 | (367) |
| EARNINGS PER SHARE (IN €) | 0,84 | 0,69 |
| DILUTED EARNINGS PER SHARE (IN €) | 0,83 | 0,68 |
| 06/30/2024 | |||
|---|---|---|---|
| (in thousands of euros) | 06/30/2025 | ||
| PROFIT (LOSS) FOR THE PERIOD | 38 710 | 31 204 | |
| Elements not recyclable in result | |||
| Revaluation of net liabilities (assets) of defined benefit plans (gross element) | -443 | -969 | |
| Revaluation of net liabilities (assets) of defined benefit plans (tax impact) | 0 | 0 | |
| Elements that can subsequently be recycled as a result | |||
| Exchange rate differences resulting from foreign operations | -46 516 | 11 781 | |
| Hedging instruments (gross element) | 2 736 | -130 | |
| Hedging instruments (tax impact) | -698 | 71 | |
| TOTAL OTHER PORTIONS OF GLOBAL EARNINGS FOR THE PERIOD, AFTER TAXES | -44 921 | 10 751 | |
| TOTAL OVERALL INCOME FOR THE PERIOD | -6 212 | 41 955 | |
| Attributable as company shareholders' equity | -6 086 | 42 224 | |
| Interest not granting control over the company | -125 | -267 |
| ASSETS (in thousands of euros) | 06/30/2025 | 12/31/2024 | |
|---|---|---|---|
| NON-CURRENT ASSETS | |||
| Goodwill | 395 313 | 419 379 | |
| Other intangible assets | 29 117 | 29 693 | |
| Tangible assets | 738 505 | 765 416 | |
| Non-current financial assets | 25 570 | 21 501 | |
| Deferred tax assets | 46 251 | 44 913 | |
| Other non-current assets | 109 | 123 | |
| TOTAL NON-CURRENT ASSETS | 1 234 865 | 1 281 025 | |
| CURRENT ASSETS | |||
| Inventories | 497 545 | 468 174 | |
| Taxes - Claim on the state | 13 397 | 12 360 | |
| Trade and other receivables | 281 706 | 244 995 | |
| Cash and cash equivalents | 255 248 | 191 660 | |
| TOTAL CURRENT ASSETS | 1 047 897 | 917 190 | |
| Assets held for sale | – | 12 068 | |
| TOTAL ASSETS | 2 282 762 | 2 210 283 |
| TOTAL EQUITY AND LIABILITIES (in thousands of euros) | 06/30/2025 | 12/31/2024 | |
|---|---|---|---|
| SHAREHOLDERS' EQUITY | |||
| Capital stock | 18 615 | 18 615 | |
| Additional paid-in-capital | – | – | |
| Treasury shares | (19 391) | (20 080) | |
| Consolidated reserves | 931 104 | 891 754 | |
| Conversion reserves | 13 464 | 59 635 | |
| Other elements of comprehensive income | (4 716) | (6 295) | |
| Profit (loss) for the period | 38 506 | 56 006 | |
| TOTAL SHAREHOLDERS' EQUITY - GROUP'S SHARE | 977 574 | 999 633 | |
| Interest not granting control over the company | 6 441 | 6 567 | |
| TOTAL SHAREHOLDERS' EQUITY | 984 014 | 1 006 200 | |
| NON-CURRENT LIABILITIES | |||
| Non-current provisions | 48 651 | 48 627 | |
| Non-current borrowings | 520 288 | 547 121 | |
| Other non-currents liabilities | 12 191 | 14 979 | |
| Deferred tax liaibilities | 45 659 | 47 973 | |
| TOTAL NON-CURRENT LIABILITIES | 626 789 | 658 700 | |
| CURRENT LIABILITIES | |||
| Current provisions | 6 880 | 15 327 | |
| Current borrowings | 254 636 | 133 070 | |
| Trade and other accounts payable | 395 838 | 378 591 | |
| Taxes due | 14 604 | 5 535 | |
| TOTAL CURRENT LIABILITIES | 671 959 | 532 523 | |
| Liabilities directly associated with assets held for sale | – | 12 860 | |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | 2 282 762 | 2 210 283 | |
| * Including short-term banking facilities | 156 208 | 39 390 |
| Consolidated cash flow statement of LISI Group | ||||
|---|---|---|---|---|
| ------------------------------------------------ | -- | -- | -- | -- |
| (in thousands of euros) | 06/30/2025 | |
|---|---|---|
| 06/30/2024 | ||
| OPERATING ACTIVITIES NET PROFIT (LOSS) |
38 710 | 31 204 |
| Elimination of net expenses not affecting cash flows: | ||
| - Depreciation, Amortization and non-current financial provisions | 45 934 | 52 631 |
| - Changes in deferred taxes | (4 324) | (1 549) |
| - Incarne on disposals, provisions for liabilities and others | 8 967 | 2 269 |
| GROSS CASH FLOW MARGIN | 89 287 | 84 555 |
| Net changes in provisions associated with ongoing operations | (501) | 1 448 |
| OPERATING CASH FLOW | 88 787 | 86 004 |
| Income tax expense elimination | 17 775 | 12 910 |
| Restatement of financial items (interest and exchange) | 29 720 | 13 060 |
| Effect of changes in inventory | (42 200) | (42 031) |
| Effect of changes in accounts receivable and accounts payable | (17 025) | 410 |
| NET CASH PROVIDED BY OR USED FOR OPERATIONS BEFORE TAX | 77 056 | 70 352 |
| Tax paid | (8 924) | (15 097) |
| CASH PROVIDED BY OR USED FOR OPERATING ACTIVITIES (A) | 68 133 | 55 256 |
| INVESTMENT ACTIVITIES | ||
| Acquisition of consolidated companies | – | – |
| Acquired cash | – | – |
| Acquisition of tangible and intangible fixed assets | (53 322) | (55 719) |
| Acquisition of financial assets | (5 000) | (5 112) |
| Change in granted loans and advances | – | 216 |
| TOTAL CASH USED FOR INVESTMENT ACTIVITIES | (58 322) | (60 615) |
| Divested cash | (6 671) | – |
| Disposal of consolidated companies | – | – |
| Disposal of tangible and intangible fixed assets | 619 | 212 |
| Disposal of financial assets | – | – |
| TOTAL CASH FROM DISPOSALS | (6 053) | 212 |
| CASH PROVIDED BY OR USED FOR INVESTMENT ACTIVITIES (B) | (64 377) | (60 403) |
| FINANCING ACTIVITIES | ||
| Capital increase | – | – |
| Capital decrease (OPRA) | – | – |
| Dividends paid to Group shareholders | (17 897) | (14 195) |
| Dividends paid to minority interests of consolidated companies | – | – |
| TOTAL CASH FROM EQUITY TRANSACTIONS | (17 897) | (14 195) |
| New long-term loans | 41 573 | 37 715 |
| New short-term loans | 1 702 | 761 |
| Repayment of long-term loans | 640 | (1 495) |
| Repayment of short-term loans | (59 018) | (72 214) |
| Net interest expense paid | (12 183) | (13 057) |
| TOTAL CASH FROM ON LOANS AND OTHER FINANCIAL LIABILITIES | (27 287) | (48 290) |
| CASH PROVIDED BY OR USED FOR FINANCING ACTIVITIES (C) | (45 184) | (62 485) |
| Effect of change in foreign exchange rates (D) | (12 445) | (926) |
| Effect of adjustments in treasury shares (D) | 644 | (715) |
| CHANGES IN CASH (A+B+C+D) | (53 230) | (69 273) |
| Cash at January 1 (E) | 152 270 | 117 353 |
| Cash at year-end (A+B+C+D+E) | 99 040 | 48 079 |
| Cash and cash equivalents | 255 248 | 151 544 |
| Short-term banking facilities | (156 208) | (103 464) |
| CLOSING CASH POSITION | 99 040 | 48 079 |
| (in thousands of euros) | Capital stock | Capital-linked premiums |
Treasury shares |
Consolidated reserves |
Conversion reserves |
Other elements of comprehensive income |
Profit for the period, Group share |
Group's share of shareholders' equity |
Minority interests |
Total shareholders' equity |
|---|---|---|---|---|---|---|---|---|---|---|
| SHAREHOLDERS' EQUITY AT JANUARY 1, 2024 |
18 615 | – (19 638) | 866 704 | 35 908 | (6 554) | 37 533 | 932 565 | 6 171 | 938 736 | |
| Profit (loss) for the period N (a) | – | – | – | – | – | – | 31 571 | 31 571 | (367) | 31 204 |
| Translation differences (b) | – | – | – | – | 11 676 | – | – | 11 676 | 105 | 11 781 |
| Payments in shares | – | – | – | 1 295 | – | – | – | 1 295 | – | 1 295 |
| Restatement of treasury shares | – | – | (505) | 13 | – | – | – | (492) | – | (492) |
| Revaluation of net liabilities (assets) of defined benefit plans (c) |
– | – | – | – | – | (969) | – | (969) | – | (969) |
| Appropriation of N-1 earnings | – | – | – | 37 533 | – | – | (37 533) | – | – | – |
| Dividends distributed | – | – | – | (14 195) | – | – | – | (14 195) | – | (14 195) |
| Restatement of financial instruments (d) | – | – | – | – | – | (54) | – | (54) | (5) | (59) |
| Various | – | – | – | (24) | – | – | – | (24) | – | (24) |
| SHAREHOLDERS' EQUITY AT JUNE 30 2024 |
18 615 | – (20 143) | 891 330 | 47 584 | (7 577) | 31 571 | 961 374 | 5 903 | 967 277 | |
| including total income and expenses reported for the year (a) + (b) + (c) + (d) |
– | – | – | – | 11 676 | (1 023) | 31 571 | 42 224 | (267) | 41 955 |
| SHAREHOLDERS' EQUITY AT JANUARY 1ST, 2025 |
18 615 | – (20 080) | 891 754 | 59 635 | (6 295) | 56 006 | 999 633 | 6 567 | 1 006 200 | |
| Profit (loss) for the period N (a) | – | – | – | – | – | – | 38 506 | 38 506 | 204 | 38 710 |
| Translation differences (b) | – | – | – | – | (46 171) | – | – | (46 171) | (345) | (46 516) |
| Payments in shares | – | – | – | 989 | – | – | – | 989 | – | 989 |
| Restatement of treasury shares | – | – | 689 | 283 | – | – | – | 972 | – | 972 |
| Revaluation of net liabilities (assets) of defined benefit plans (c) |
– | – | – | – | – | (443) | – | (443) | – | (443) |
| Appropriation of N-1 earnings | – | – | – | 56 006 | – | – | (56 006) | – | – | – |
| Dividends distributed | – | – | – | (17 897) | – | – | – | (17 897) | – | (17 897) |
| Restatement of financial instruments (d) | – | – | – | – | – | 2 022 | – | 2 022 | 16 | 2 038 |
| Various | – | – | – | (38) | – | – | – | (38) | – | (38) |
| SHAREHOLDERS' EQUITY AT JUNE 30 2025 |
18 615 | – (19 391) | 931 104 | 13 464 | (4 716) | 38 506 | 977 574 | 6 441 | 984 014 | |
| including total income and expenses reported for the year (a) + (b) + (c) + (d) |
– | – | – | – | (46 171) | 1 579 | 38 506 | (6 086) | (125) | (6 212) |
Have a question? We'll get back to you promptly.